

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Canceled)

2. (Currently Amended) A eukaryotic cell *in vitro* comprising a vector, said ~~vector~~comprising vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequence encoding the selectable marker ~~and/or~~ or the unpaired splice donor or both and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter and wherein said unpaired splice donor is spliced to a splice acceptor of said endogenous gene to produce said fusion transcript, and coding sequence in said endogenous gene is translated.

3. (Currently Amended) A eukaryotic cell *in vitro* comprising a vector, said vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequence encoding the selectable marker ~~and/or~~ or the unpaired splice donor or both and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter, and coding sequence in said endogenous gene is translated.

4. (Previously Presented) The eukaryotic cell of claim 2 or 3, wherein said cell is an animal cell.

5. (Previously Presented) The eukaryotic cell of claim 4, wherein said animal cell is selected from the group consisting of a mammalian cell, an insect cell, an avian cell, an annelid cell, an amphibian cell, a reptilian cell, and a fish cell.
6. (Previously Presented) The eukaryotic cell of claim 4, wherein said animal cell is a mammalian cell.
7. (Previously Presented) The eukaryotic cell of claim 6, wherein said mammalian cell is a human cell.
8. (Previously Presented) The eukaryotic cell of claim 2 or 3, wherein said cell is a plant cell.
9. (Previously Presented) The eukaryotic cell of claim 2 or 3, wherein said cell is a fungal cell.
10. (Previously Presented) The eukaryotic cell of claim 9, wherein said fungal cell is a yeast cell.
11. (Currently Amended) The eukaryotic cell of claim 4, wherein said cell is an isolated and cloned cell.
12. (Withdrawn) A vector comprising (i) a first promoter that functions in a eukaryotic cell operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, said vector further comprising one or more transposition signals.
13. (Withdrawn) A vector comprising (i) a first promoter that functions in a eukaryotic cell operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, said vector further comprising one or more viral originals of replication
14. (Withdrawn) A vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, said vector further comprising one or more viral replication factor genes.

15. (Withdrawn) The vector of claim 13, wherein said viral origin of replication is selected from the group consisting of Epstein Barr virus ori P and SV40 ori.
16. (Withdrawn) A vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, said vector further comprising genomic DNA.
17. (Withdrawn) A eukaryotic cell *in vitro* comprising the vector of claim 12.
18. (Withdrawn) A eukaryotic cell *in vitro* comprising the vector of claim 13.
19. (Withdrawn) A eukaryotic cell *in vitro* comprising the vector of claim 14.
20. (Withdrawn) A eukaryotic cell *in vitro* comprising the vector of claim 16.
21. (Withdrawn) The cell of any one of claims 17-20, wherein said cell is an isolated cell.
22. (Currently Amended) A library of eukaryotic cells *in vitro* comprising a vector, said vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequences encoding the selectable marker ~~and/or~~ or the unpaired splice donor or both and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter and wherein said unpaired splice donor is spliced to a splice acceptor of said endogenous gene to produce said fusion transcript, and coding sequence in said endogenous gene is translated.
23. (Withdrawn) A library of eukaryotic cells *in vitro* comprising the vector of any of claims 12-14 or 16.

24. (Withdrawn) A method for increasing protein expression of an endogenous gene in a eukaryotic cell *in vitro*, said method comprising introducing a vector into said eukaryotic cell, said vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequence encoding the selectable marker and/or the unpaired splice donor and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter and wherein said unpaired splice donor is spliced to a splice acceptor of said endogenous gene to produce said fusion transcript, and coding sequence in said endogenous gene is translated.

25. (Withdrawn) A method for increasing protein expression of an endogenous gene in a eukaryotic cell *in vitro*, said method comprising introducing a vector into said eukaryotic cell, said vector comprising (i) a first promoter operably linked to a nucleotide sequence encoding a selectable marker, wherein said nucleotide sequence lacks a functional polyadenylation signal, and (ii) a second promoter operably linked to an unpaired splice donor into said cell, wherein said vector is non-homologously integrated into the genome of said eukaryotic cell in such a way that a fusion transcript comprising the nucleotide sequence encoding the selectable marker and/or the unpaired splice donor and one or more exons of an endogenous gene is expressed under the control of said first or said second promoter, and coding sequence in said endogenous gene is translated.

26. (Currently Amended) The ~~vector cell~~ of claim 2 or 3, wherein said ~~promoter is~~ promoters are selected from the group consisting of a CMV immediate early gene promoter, an SV40 T antigen promoter, a tetracycline-inducible promoter, and a  $\beta$ -actin promoter.

27. (Currently Amended) The ~~vector~~ cell of claim 2 or 3, wherein said selectable marker is selected from the group consisting of neomycin, hypoxanthine phosphoribosyl transferase, puromycin, dihydroorotase, glutamine synthetase, histidine D, carbamyl phosphate synthase, dihydrofolate reductase, multidrug resistance 1, aspartate transcarbamylase, xanthine-guanine phosphoribosyl transferase, adenosine deaminase, and thymidine kinase.

Applicants do not believe that any fees are due with this filing. In the event that fees are incurred, however, the Commissioner is hereby authorized to charge such fees to Deposit Account 20-0809. The applicant(s) hereby authorizes the Commissioner under 37 C.F.R. §1.136(a)(3) to treat any paper that is filed in this application which requires an extension of time as incorporating a request for such an extension.

Respectfully submitted,



Anne Brown  
Reg. No. 36,463

November 5, 2008  
THOMPSON HINE LLP  
10 West Second Street  
2000 Courthouse Plaza, N.E.  
Dayton, Ohio 45402  
(216) 566-8921

11416022.1